Of note, interruption of CCL2 inhibition in models of metastatic breast cancer accelerated metastases and death (259). This highlights our incomplete understanding of the CCL2-CCR2 signaling network and that caution should be taken when considering targeting this axis in metastatic diseases. Here, CCR2 is linked to breast carcinoma.